ZBIO (Zenas BioPharma) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $31.88
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma NonCurrent Deferred Liabilities?

Zenas BioPharma ZBIO +1.50% 12 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zenas BioPharma's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Zenas BioPharma NonCurrent Deferred Liabilities Related Terms

Zenas BioPharma NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma NonCurrent Deferred Liabilities Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Zenas BioPharma (ZBIO) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's NonCurrent Deferred Liabilities too high?
Zenas BioPharma's current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's NonCurrent Deferred Liabilities compare to ADMA and PGEN?
Zenas BioPharma's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.88
Price